{"id":389020,"date":"2024-12-10T00:00:00","date_gmt":"2024-12-10T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2024-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2024\/"},"modified":"2026-04-27T11:15:01","modified_gmt":"2026-04-27T11:15:01","slug":"dlsfon0002-2024-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2024","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0002-2024-biopharma-colorectal-cancer-disease-landscape-forecast-g7-2024\/","title":{"rendered":"Colorectal Cancer | Disease Landscape &#038; Forecast | G7 | 2024"},"content":{"rendered":"<p>Doublet or triplet chemotherapy alone or in combination with angiogenesis inhibitors remains the cornerstone of treatment for metastatic colorectal cancer. Patients without <em>RAS<\/em> mutations also benefit from EGFR inhibitors (Merck &#038; Co. \/ Eli Lilly\u2019s Erbitux and Amgen\u2019s Vectibix), which are recommended for first-line treatment of patients with left-sided tumors. Notably, additional targeted therapies for specific molecular subtypes have been developed: immune checkpoint inhibitors (Merck &#038; Co.\u2019s Keytruda and Bristol Myers Squibb\u2019s Opdivo and Yervoy) for MSI-high and\/or MMR-deficient tumors; BRAF inhibitors (Array BioPharma \/ Pfizer\u2019s Braftovi) for metastatic colorectal cancer with a <em>BRAF V600E <\/em>mutation; and HER2-targeted agents in some markets (Chugai\u2019s Perjeta and trastuzumab and Seagen\u2019s Tukysa) for HER2-positive metastatic disease. Most therapies in late-phase development are intended to treat other genomic alterations (i.e., <em>KRAS<\/em> G12C mutation) or expand the immunotherapy-based approaches for treating MSS and\/or pMMR tumors.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>How large are the drug-treatable colorectal cancer populations? How do patient populations differ by disease stage and key biomarkers?<\/li>\n<li>What are interviewed experts\u2019 views on current and emerging late-phase therapies, and what strategies are companies pursuing to secure uptake and share in the colorectal cancer market?<\/li>\n<li>What are the key drivers and constraints in the colorectal cancer therapy market, and how will they change over the forecast period?<\/li>\n<\/ul>\n<p><strong>Geography: <\/strong>United States, EU5, Japan<\/p>\n<p><strong>Primary research: <\/strong>19 country-specific interviews with thought-leading medical oncologists \/ urologists. Supported by survey data collected for this and other Clarivate research.<\/p>\n<p><strong>Epidemiology: <\/strong>Diagnosed and recurrent incidence of colorectal cancer; drug-treatable and -treated cases by country, disease stage, tumor side, BRAF status, and RAS status<\/p>\n<p><strong>Forecast: <\/strong>10-year, annualized, drug-level sales and patient share of key colorectal cancer therapies through 2033, segmented by brands \/ generics and epidemiological subpopulations<\/p>\n<p><strong>Drug treatments: <\/strong>Coverage of key current and emerging therapies<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Key features<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will be updated throughout the year to provide timely insights and analyses as material indication-specific news and events unfold.<\/p>\n<p>Disease Landscape &#038; Forecast features a Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389020","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-colorectal-cancer","biopharma-date-985"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389020","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389020\/revisions"}],"predecessor-version":[{"id":575872,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389020\/revisions\/575872"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389020"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}